Luminex Discloses GenturaDx Loss of $19.8M in 2011, $18.5M in H1 2012 | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex today disclosed the finances of GenturaDx, a molecular diagnostic test firm that it acquired for $50 million during the summer.

In a document filed with the US Securities and Exchange Commission, Luminex said that for full-year 2011, GenturaDx recorded no revenues and a net loss of $19.8 million. The company spent $10.1 million on R&D and $3.5 million on SG&A.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.